Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9889358 | 0.95 | MMP1 (0.41) | MMP1MMP2MMP3MMP9F2 | |
| SCHEMBL24116790 | 0.67 | HPGD (0.37) | ALDH1A1 | |
| Phosphoric Acid SCHEMBL17022775 | 0.67 | F2 (0.45) | MMP1MMP2MMP3MMP9F2 | |
| SCHEMBL24116789 | 0.66 | — | — | |
| SCHEMBL14595297 | 0.65 | — | — | |
| SCHEMBL15588635 | 0.64 | F2 (0.46) | F2ALDH1A1 | |
| SCHEMBL15588798 | 0.62 | F2 (0.50) | MMP1MMP2MMP3MMP9F2 | |
| SCHEMBL15588799 | 0.62 | F2 (0.50) | MMP1MMP2MMP3MMP9F2 | |
| Hydrochloric Acid SCHEMBL15560657 | 0.62 | F2 (0.43) | F2ALDH1A1 | |
| SCHEMBL4586883 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285338-A9 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | WASHINGTON UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20140045798-A1 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF | GENCIA CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130072462-A1 | Mitochondrial Compositions and Uses Thereof | GENCIA CORPORATION (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | AVICENA GROUP, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100329997-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045798-A1 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF | CS, UQCRC1, UQCRC2 | MMP1 1967/4885MMP2 1876/4885MMP3 2162/4885 |
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | PC, CKMT1A; CKMT1B, CHEK1 | MMP1 1796/4885MMP2 1970/4885MMP3 862/4885 |
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | PC, CKMT1A; CKMT1B, CHEK1 | MMP1 1796/4885MMP2 1970/4885MMP3 862/4885 |
| US-20100329997-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | MMP1 1796/4885MMP2 1970/4885MMP3 862/4885 |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | MMP1 1796/4885MMP2 1970/4885MMP3 862/4885 |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | MMP1 1796/4885MMP2 1970/4885MMP3 862/4885 |
| US-20230285338-A9 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | CX3CR1, CD68, FYN | MMP1 1789/4885MMP2 2247/4885MMP3 1492/4885 |
| US-20130072462-A1 | Mitochondrial Compositions and Uses Thereof | UQCRC1, CS, UQCRC2 | MMP1 2274/4885MMP2 2078/4885MMP3 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.